Vor Biopharma Inc. (VOR) Stock Price & Analysis
Vor Biopharma Inc. (VOR) closed at USD 20.65 on Wednesday, October 28, 2026, up 5.68% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 19.54; the Oct 28, 2026 session ranged USD 19.38–20.81 on volume of 1,011,532 shares. Market capitalization is $1.22B, with a 52-week range of USD 6.5–26.76 (NMS). Source: Nexqual, retrieved October 29, 2026 at 13:29 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VOR.md
Key facts (VOR)
- Valuation: P/E 1.9x.
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $24.7M; 4 not under a Rule 10b5-1 plan ($24.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 39 (range 27–50).
- Total return with dividends: 1Y -19.0% vs S&P 500 +13.6%; 5Y -93.4% vs S&P 500 +79.8%.
- Next earnings: 2026-11-12, EPS estimate USD -0.72, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VOR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$69.0M | -$93.4M | -$126M | -$121M | -$372M | -$147M |
| Net income | -$68.9M | -$92.1M | -$118M | -$117M | -$696M | $628M |
| EPS (diluted) | -$42.00 | -$46.60 | -$35.00 | -$34.03 | -$70.50 | — |
| Free cash flow | -$73.0M | -$93.6M | -$101M | -$99.9M | -$144M | -$141M |
| Cash + short-term investments | $207M | $230M | $137M | $91.9M | $455M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (VOR)
P/E 1.9x · FCF yield -11.53% · Earnings yield 51.39%
Insider sales (SEC Form 4, open-market, last ~7 months) (VOR)
0 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-16 | Ra Capital Management, L.P. | 213 | $4K | 0% | No | Too little history (no open-market trades in 2023 or 2024) | |
| 2026-04-22 | Ra Capital Management, L.P. | Director | 165,150 | $2.6M | 6.4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-17…2026-04-20 | Ra Capital Management, L.P. | Director | 630,374 | $10.2M | 19.7% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-13…2026-04-15 | Ra Capital Management, L.P. | Director | 737,989 | $11.9M | 18.8% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (VOR)
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 39 (low 27, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | William Blair | Initiated | Outperform | |
| 2026-08-12 | Wedbush | Target raised | Neutral | $18 → $27 |
Total return (dividends reinvested) (VOR)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -19.0% | -93.4% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -19.1% | -41.9% |
| Volatility (annualized) | 112.6% | 132.2% |
| Max drawdown | -73.1% (Oct 2025→Nov 2025) | -99.2% (Nov 2021→May 2025) |
VOR major shareholder filing: Schedule 13D/A, Jul 21, 2026
RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah filed a Schedule 13D/A with the SEC on Jul 21, 2026, reporting up to 19.90% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the Issuer.
Source: SEC EDGAR, Schedule 13D/A filed Jul 21, 2026. Quoted word for word; Nexqual adds no interpretation.
VOR earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | $307.53 | −$1.19 | Beat +$308.72 | -0.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
VOR recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 14, 2026 | Schedule 13G/A | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC: 9.9% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G/A | Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P.: 4.2% of shares, passive 5%+ holder (amended) |
| Aug 13, 2026 | Schedule 13G/A | Verve Capital Limited: 6.3% of shares, passive 5%+ holder (amended) |
| Aug 11, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 7, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 12.0% of shares, passive 5%+ holder (amended) |
| Aug 6, 2026 | Schedule 13G | FMR LLC, Abigail P. Johnson: 9.1% of shares, passive 5%+ holder |
| Jul 30, 2026 | Schedule 13G | BlackRock, Inc.: 5.7% of shares, passive 5%+ holder |
| Jul 21, 2026 | Schedule 13D/A | RA Capital Management, L.P., Peter Kolchinsky: 19.9% of shares, 5%+ holder that may seek to influence the company (amended) “Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the…” |
| Jul 7, 2026 | 8-K | Director or executive officer change, or pay arrangement “(b) Resignation of Andrew Levin, M.D., Ph.D. as a Director On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the "Board") of Vor Biopharma Inc. (the "Company"), delivered his notice of resignation, effective immediately. Dr. Levin's decision to resign was not as a result of any disagreement with the Company. The Board thanks Dr. Levin for his service to the Company. (d) Appointment of David Zaccardelli, Pharm.D., as a Director On July 7, 2026, the Board appointed David Zaccardelli,…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
VOR suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | RA Capital Healthcare Fund | “For example, in December 2022 we filed a registration statement on Form S-3 to register the resale of up to 581,395 shares of common stock held by RA Capital Healthcare Fund L.P. which were purchased from us in a private placement, and in January 2025 we filed a registration statement on Form S-3 to register the resale of up to an aggregate of 6,285,515 shares of common stock held by Reprogrammed Interchange LLC a…” |
| Customer | Reprogrammed Interchange | “For example, in December 2022 we filed a registration statement on Form S-3 to register the resale of up to 581,395 shares of common stock held by RA Capital Healthcare Fund L.P. which were purchased from us in a private placement, and in January 2025 we filed a registration statement on Form S-3 to register the resale of up to an aggregate of 6,285,515 shares of common stock held by Reprogrammed Interchange LLC a…” |
| Customer | RA Capital Management | “For example, in December 2022 we filed a registration statement on Form S-3 to register the resale of up to 581,395 shares of common stock held by RA Capital Healthcare Fund L.P. which were purchased from us in a private placement, and in January 2025 we filed a registration statement on Form S-3 to register the resale of up to an aggregate of 6,285,515 shares of common stock held by Reprogrammed Interchange LLC a…” |
| Partner | RemeGen | “Pursuant to our license agreement with RemeGen, we were granted an exclusive license to develop and commercialize telitacicept outside of the Greater China region, which includes mainland China, Hong Kong, Macau and Taiwan.” |
| Partner | Nicolaus & Company | “In December 2022, we entered into a Sales Agreement with Stifel, Nicolaus & Company, Incorporated ("Stifel") as the agent (the "Stifel ATM Facility").” |
| Competitor | Johnson & Johnson (JNJ) | “The autoimmune field is a competitive landscape involving multiple fusion protein class members (atacicept, povetacicept), monoclonal antibodies, other biologics, chimeric antigen receptor (CAR) T cells and small molecules either already marketed or in development by many different companies including, but not limited to Alexion, Amgen, Argenx, Dianthus, Johnson & Johnson, UCB, and Vertex.” |
Quoted from the company's 10-K filed Mar 30, 2026.
VOR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.72 | $-0.77 | +$0.05 | $0 | 1 |
| Next quarter (ends Dec 2026) | $-0.77 | $-0.93 | +$0.16 | $0 | 1 |
| Current fiscal year (ends Dec 2026) | $-6.88 | $-6.90 | +$0.02 | $0 | 2 |
| Next fiscal year (ends Dec 2027) | $-3.67 | $-3.74 | +$0.07 | $0 | 3 |
VOR options: expected move
Options price a move of about ±23.0% (±$4.73) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 1 reports the stock moved ±0.2% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 116.4% | ±23.0% |
| Dec 18, 2026 | 50 | 103.9% | ±30.3% |
| Feb 19, 2027 | 113 | 94.4% | ±40.4% |
| May 21, 2027 | 204 | 127.3% | ±70.9% |
30-day implied volatility 93.8% vs 64.1% realized over the last 30 trading days. Put/call ratio (volume) 0.09. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 13:29 UTC)
| Price | USD 20.65 |
|---|---|
| Change | ▲ 5.68% (up) |
| Previous Close | USD 19.54 |
| Open | USD 19.5 |
| Day Range | USD 19.38 – 20.81 |
| 52-Week Range | USD 6.5 – 26.76 |
| Volume | 1,011,532 shares |
| Market Cap | $1.22B |
| Exchange | NMS |
Technical Analysis (VOR)
Nexqual's technical model rates VOR "NEUTRAL" based on 3 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 13:29 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 56.06 (neutral) |
| vs SMA50 | Below (USD 20.87) |
| MACD | -0.3 (negative) |
Analyst Ratings (VOR)
Wall Street analysts rate VOR "Buy" based on 10 analysts, with a mean price target of USD 39 (range USD 27–50), per Nexqual as of October 29, 2026 at 13:29 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 39 |
| High Target | USD 50 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (VOR)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.72 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.8 vs est -0.7 ▼ miss |
| 2026-03-31 | USD -0.73 vs est -0.78 ▲ beat |
| 2025-12-31 | USD 307.53 vs est -1.19 ▲ beat |
| 2025-09-30 | USD -121.63 vs est -4.1 ▼ miss |
Source: Nexqual, October 29, 2026 at 13:29 UTC.
Financials & Fundamentals (VOR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 19.15 |
| Total Cash | $466.13M |
| Total Debt | $2.88M |
Source: Nexqual, October 29, 2026 at 13:29 UTC.
Financial Health Score (VOR)
Nexqual rates Vor Biopharma Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 13:29 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $466M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$143M (FY ended Dec 2025, 10-K) |
| Efficiency | Strong — ROE not meaningful (negative equity); ROA 130.5% (last 4 quarters, SEC) |
Ownership (VOR)
| Insider Ownership | +9.26% |
|---|---|
| Institutional Ownership | +86.80% |
| Shares Outstanding | 59.16M |
| Float | 37.23M |
| Short % of Float | +14.81% |
Source: Nexqual, October 29, 2026 at 13:29 UTC.
Leadership (VOR)
Vor Biopharma Inc. is led by Jean-Paul Kress, Chairman, President & CEO, per Nexqual as of October 29, 2026 at 13:29 UTC.
| Chairman, President & CEO | Jean-Paul Kress |
|---|---|
| Chief Business Officer & CFO | Sandesh Mahatme L.L.M. |
| Scientific Founder & Chairman of Scientific Advisory Board | Siddhartha Mukherjee DPHIL |
Major Backers & Investors (VOR)
Notable institutional backers of Vor Biopharma Inc. include TCG Crossover Management, LLC, FMR, LLC, Fidelity, according to Nexqual as of October 29, 2026 at 13:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 9.59% |
| FMR, LLC | 8.34% |
| Fidelity | 8.1% |
| FCPM III Services B.V. | 6.96% |
| Venrock Adviser, LLC | 5.14% |
| Frazier Life Sciences Management, L.P. | 4.3% |
| RA Capital Management, L.P. | 4.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.86% |
| State Street | 4.42% |
| Vanguard Group | 3.52% |
Source: Nexqual, October 29, 2026 at 13:29 UTC.
From Vor Biopharma Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We plan to focus our efforts in these regions because we believe the patient populations and medical specialists for the indications we are targeting are sufficiently concentrated to allow us to effectively promote our product candidate, if approved for commercial sale, with a targeted sales team.
Partnerships
- In August and September 2025, we sold certain intellectual property related to trem-cel, VCAR33 and VADC45 and assigned certain license agreements related to these product candidates to the buyers, including the exclusive license agreement with The Trustees of Columbia University in the City of New York and patent license agreement with the U.S.
- Pursuant to our license agreement with RemeGen, we were granted an exclusive license to develop and commercialize telitacicept outside of the Greater China region, which includes mainland China, Hong Kong, Macau and Taiwan.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS.
- Risks Related to Our Relationships with Third Parties
- We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.
- We rely on third parties, such as CROs, clinical data management organizations, and clinical investigators, to conduct our clinical trials. Any of these third parties may terminate their engagements with us at any time under certain criteria. If we need to enter into alternative arrangements, it may delay our product development activities.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 13:29 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt